With the planned purchase, Boston Scientific will gain several thrombectomy devices to remove clots from blood vessels.
Boston Scientific to acquire Penumbra for $14.5B
Boston Scientific has agreed to acquire Penumbra for $14.5 billion in cash and stock, at $374 per share, valuing Penumbra roughly 19% above its recent price. The deal, expected to close in 2026 subject to shareholder approvals and customary closing conditions, would expand Boston Scientific’s portfolio into thrombectomy and embolization devices. Penumbra is projected to…